{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T12:06:19Z","timestamp":1773403579750,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,3,5]],"date-time":"2015-03-05T00:00:00Z","timestamp":1425513600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1007\/s00280-015-2703-1","type":"journal-article","created":{"date-parts":[[2015,3,4]],"date-time":"2015-03-04T14:57:43Z","timestamp":1425481063000},"page":"929-939","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["First-in-human, phase I\/IIa dose-escalation and safety study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy"],"prefix":"10.1007","volume":"75","author":[{"given":"Noa","family":"Avisar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liat","family":"Adar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Bock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Udo","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Barash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurie","family":"Pukac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,3,5]]},"reference":[{"key":"2703_CR1","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s00520-008-0430-4","volume":"16","author":"R Pettengell","year":"2008","unstructured":"Pettengell R, Schwenkglenks M, Leonard R et al (2008) Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. Support Care Cancer 16:1299\u20131309","journal-title":"Support Care Cancer"},{"key":"2703_CR2","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1586\/era.12.172","volume":"13","author":"M Joerger","year":"2013","unstructured":"Joerger M, Thurlimann B (2013) Chemotherapy regimens in early breast cancer: major controversies and future outlook. Exp Rev Anticancer Ther 13:165\u2013178","journal-title":"Exp Rev Anticancer Ther"},{"key":"2703_CR3","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/1471-2407-8-332","volume":"8","author":"A Giglio del","year":"2008","unstructured":"del Giglio A, Eniu A, Ganea-Motan D, Topuzov E, Lubenau H (2008) XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel\/doxorubicin chemotherapy. BMC Cancer 8:332\u2013338","journal-title":"BMC Cancer"},{"key":"2703_CR4","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1200\/JCO.2004.08.125","volume":"22","author":"E Alba","year":"2004","unstructured":"Alba E, Martin M, Ramos M et al (2004) Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study. J Clin Oncol 22:2587\u20132593","journal-title":"J Clin Oncol"},{"key":"2703_CR5","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1200\/JCO.2003.04.040","volume":"21","author":"JM Nabholtz","year":"2003","unstructured":"Nabholtz JM, Falkson C, Campos D et al (2003) Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 21:968\u2013975","journal-title":"J Clin Oncol"},{"key":"2703_CR6","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199107183250305","volume":"325","author":"J Crawford","year":"1991","unstructured":"Crawford J, Ozer H, Stoller R et al (1991) Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325:164\u2013170","journal-title":"N Engl J Med"},{"key":"2703_CR7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/08977190500055836","volume":"23","author":"AW Roberts","year":"2005","unstructured":"Roberts AW (2005) G-CSF: a key regulator of neutrophil production, but that\u2019s not all! Growth Factors 23:33\u201341","journal-title":"Growth Factors"},{"key":"2703_CR8","unstructured":"Neulasta [package insert] (2014) Amgen Inc., Thousand Oaks, CA"},{"key":"2703_CR9","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2165\/11586040-000000000-00000","volume":"50","author":"BB Yang","year":"2011","unstructured":"Yang BB, Kido A (2011) Pharmacokinetics and pharmacodynamics of pegfilgrastim. Clin Pharmacokinet 50:295\u2013306","journal-title":"Clin Pharmacokinet"},{"key":"2703_CR10","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jconrel.2011.09.069","volume":"157","author":"B Elsadek","year":"2012","unstructured":"Elsadek B, Kratz F (2012) Impact of albumin on drug delivery\u2013new applications on the horizon. J Control Release 157:4\u201328","journal-title":"J Control Release"},{"key":"2703_CR11","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649\u2013655","journal-title":"Am J Clin Oncol"},{"key":"2703_CR12","unstructured":"NCCN Clinical Practice Guidelines in Oncology (2014) Myeloid Growth Factors v.2.2014. National Comprehensive Cancer Network. www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp . Accessed 23 Dec 2014"},{"key":"2703_CR13","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","volume":"24","author":"TJ Smith","year":"2006","unstructured":"Smith TJ, Khatcheressian J, Lyman GH et al (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24:3187\u20133205","journal-title":"J Clin Oncol"},{"key":"2703_CR14","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"MS Aapro","year":"2011","unstructured":"Aapro MS, Bohlius J, Cameron DA et al (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47:8\u201332","journal-title":"Eur J Cancer"},{"key":"2703_CR15","unstructured":"Neupogen [package insert] (2013) Amgen Inc., Thousand Oaks, CA"},{"key":"2703_CR16","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/S0301-472X(99)00112-5","volume":"27","author":"G Molineux","year":"1999","unstructured":"Molineux G, Kinstler O, Briddell B et al (1999) A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol 27:1724\u20131734","journal-title":"Exp Hematol"},{"key":"2703_CR17","doi-asserted-by":"crossref","first-page":"5526","DOI":"10.1016\/j.bbagen.2013.04.023","volume":"1830","author":"D Sleep","year":"2013","unstructured":"Sleep D, Cameron J, Evans LR (2013) Albumin as a versatile platform for drug half-life extension. Biochim Biophys Acta 1830:5526\u20135534","journal-title":"Biochim Biophys Acta"},{"key":"2703_CR18","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1023\/A:1020917732218","volume":"19","author":"W Halpern","year":"2002","unstructured":"Halpern W, Riccobene TA, Agostini H et al (2002) Albugranin, a recombinant human granulocyte colony stimulating factor (G-CSF) genetically fused to recombinant human albumin induces prolonged myelopoietic effects in mice and monkeys. Pharm Res 19:1720\u20131729","journal-title":"Pharm Res"},{"key":"2703_CR19","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1200\/JCO.2000.18.13.2522","volume":"18","author":"E Johnston","year":"2000","unstructured":"Johnston E, Crawford J, Blackwell S et al (2000) Randomized, dose-escalation study of SD\/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 18:2522\u20132528","journal-title":"J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-015-2703-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-015-2703-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-015-2703-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T16:52:24Z","timestamp":1566406344000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-015-2703-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,5]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["2703"],"URL":"https:\/\/doi.org\/10.1007\/s00280-015-2703-1","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,5]]}}}